GW Pharmaceuticals is preparing to launch its cannabis medication Epidiolex in the United States (US).
The news comes after the Drug Enforcement Administration (DEA) rescheduled Epidiolex to a Schedule V drug – one that requires the least amount of restrictions.
Once Epidiolex is launched in the US, doctors can prescribe it to their patients to treat the symptoms of epilepsy.
Epidiolex contains cannabidiol (CBD) – the non-intoxicating component of the cannabis plant.
“We are pleased that the DEA has placed Epidiolex in the lowest restriction Schedule, because it will help ensure that patients with LGS and Dravet syndrome, two of the most debilitating forms of epilepsy, can access this important new treatment option through their physicians,” said Justin Gover, chief executive officer of GW Pharma.
He added: “With this final step in the regulatory process completed, we are working hard to make Epidiolex available within the next six weeks as we know there is excitement for a standardized version of cannabidiol that has undergone the rigor of controlled clinical trials and been approved by the FDA.”
GW Pharma obtained FDA approval for the medicine in June. They expect the drug to be available in the US in about six weeks.